Clal Biotechnology | CBI - Current Liabilities


Clal Biotechnology reported ILS6.66M in Current Liabilities for its fiscal quarter ending in December of 2023.





Current Liabilities Change Date
Arca Biopharma USD 22.97M 6.34M Jun/2026
aTyr Pharma USD 11.4M 303K Jun/2026
Bio Path USD 9.15M 468K Mar/2026
Brainstorm Cell Therapeutics USD 12.38M 621K Jun/2026
Cara Therapeutics USD 11.26M 216K Mar/2026
Clal Biotechnology ILS 6.66M 3.75M Dec/2023
Compugen USD 22.04M 533K Mar/2026
Immunic USD 38.36M 7.74M Mar/2026
Minerva Neurosciences USD 2.29M 381K Dec/2025
RedHill Biopharma USD 19.22M 3.07M Dec/2025
TherapeuticsMD USD 5.82M 655K Jun/2024